Lifescience Dynamics Limited’s Post

Since their launch, CAR-T therapies have remained entrenched in uncertainties around their efficacy and safety. Over time, real-world data has aided in easing this uncertainty, which may drive significant changes in how CAR-T therapies are reimbursed. Join us at ISPOR, Europe to discuss how real-world data may drive the evolution of CAR-T reimbursement (19th November 2024, 3.15pm CET).  #ISPOREurope #LifescienceDynamics #ISPOR #ISPOR2024 #pharma #biotech #CAR_T #Immunotherapy

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics